marketing analytics
PR Newswire
Published on : Nov 18, 2026
Pharmaceutical companies are increasingly using artificial intelligence to coordinate sales and marketing activity, identify healthcare professionals (HCPs) and anticipate potential treatment demand. ODAIA has raised $15 million in Series C financing to expand its predictive commercial intelligence platform across enterprise pharmaceutical customers. The round, led by Monograph Capital and anchored by strategic investor PHM, also establishes PHM as ODAIA's exclusive U.S. agency partner, connecting predictive analytics with healthcare media planning and activation.
The financing will support ODAIA's expansion within existing enterprise pharma accounts and further development of its commercial intelligence platform. The company says its technology helps biopharmaceutical organizations predict patient journeys, identify potential missed prescription opportunities and determine which physicians to engage, through which channels and at what time.
Monograph Capital led the round, with PHM, the U.S. health media agency within Publicis Groupe, serving as an anchor strategic investor. Existing investors returning to the round include BDC Capital, Flint Capital, Innospark Ventures and Graphite Ventures, which participated in the Series A, alongside Threshold Ventures and Wittington Ventures from the Series B.
The investment comes as pharmaceutical commercial teams face pressure to make better use of fragmented data and coordinate physician engagement across sales representatives, digital channels and marketing operations.
A central problem ODAIA is targeting is the separation of commercial data across pharmaceutical organizations. Brand, marketing and field sales teams can operate with different information about the same healthcare professional, making it difficult to maintain a consistent engagement strategy.
ODAIA's platform combines data sources, field sales activity and digital engagement signals to create a shared view of HCPs. Its Brand Strategy Studio allows brand teams to define commercial strategy, which the company's decision engines translate into recommendations about physician prioritization, channels, timing and messaging.
The platform's Field Intelligence capabilities provide prioritized call plans to sales representatives through their existing CRM systems. Marketing Intelligence supports individualized HCP journeys across digital and partner channels.
This approach is intended to reduce the need to build separate analytical workflows for each brand or therapeutic area. ODAIA says expanding its platform to additional brands can be handled through configuration, rather than requiring a separate implementation and dedicated team for every deployment.
The company also emphasizes recommendation explainability. It says each recommendation includes the reasoning behind it, allowing commercial and compliance teams to examine why a particular HCP or engagement opportunity has been prioritized.
Alongside the financing, ODAIA signed a commercial Platform Agreement making PHM its exclusive agency partner in the United States.
The arrangement brings together ODAIA's predictive commercial intelligence with PHM's healthcare media capabilities. The companies intend to connect signals from digital media and pharmaceutical field sales, helping clients coordinate physician engagement across channels.
ODAIA will continue working directly with pharmaceutical companies. Its platform is designed to operate alongside customers' existing CRM systems, internal analytics models and data infrastructure rather than requiring them to replace those systems.
The partnership could strengthen the connection between identifying a physician engagement opportunity and activating media around it. However, the announcement does not disclose specific client deployments, revenue commitments or performance benchmarks associated with the agreement.
ODAIA CEO and co-founder Philip Poulidis said the company's focus has shifted from helping individual field teams prioritize activity toward providing commercial intelligence infrastructure that can scale across brands, marketing and field organizations.
That ambition reflects a wider challenge in pharmaceutical AI adoption: demonstrating value in one use case is different from deploying consistent, governed systems across an entire enterprise portfolio.
The company says its platform measures engagement and prescription lift, feeding results back into subsequent recommendations. If implemented effectively, this feedback loop could help commercial teams adjust targeting and channel strategies as market conditions change.
The Series C gives ODAIA additional capital to pursue that expansion. Its longer-term opportunity will depend on demonstrating measurable commercial outcomes, maintaining data quality and ensuring AI recommendations fit the regulatory and operational requirements of pharmaceutical businesses.
Pharmaceutical companies are investing in AI to improve commercial planning, physician engagement and the allocation of sales and marketing resources. These applications depend on combining data that may otherwise sit across CRM platforms, analytics systems, media channels and field operations.
ODAIA operates in a specialized part of the healthcare technology market: predictive commercial intelligence for life sciences. Its proposition differs from general-purpose CRM and marketing automation software by focusing on pharmaceutical workflows, HCP prioritization and patient journey signals.
The challenge is turning predictive insights into coordinated action while maintaining transparency, data governance and compliance. This is particularly important in pharma, where commercial engagement must operate within strict industry and regulatory requirements.
ODAIA's Series C financing and PHM partnership give the company two complementary growth opportunities: expanding its technology across existing enterprise customers and extending its reach through a major healthcare media agency.
The strategic value will depend on whether the platform can scale across multiple brands and therapeutic areas without creating additional implementation complexity. Its ability to connect field activity with digital engagement could also help pharmaceutical companies evaluate commercial performance across channels.
However, the announcement does not disclose the platform's revenue, customer count, prescription-lift results or the financial terms of the PHM agreement. Those measures will be important in assessing how effectively ODAIA converts predictive intelligence into measurable business outcomes.
ODAIA secures $15 million: The Series C financing will support enterprise expansion and continued development of its predictive commercial intelligence platform.
PHM becomes exclusive U.S. agency partner: The Publicis Groupe health media agency will connect ODAIA's intelligence capabilities with healthcare media activation.
HCP engagement becomes more coordinated: The platform connects field sales, digital engagement and brand strategy to support physician prioritization across channels.
AI recommendations include explanations: ODAIA says its platform provides reasoning behind recommendations, supporting review by commercial and compliance teams.
Enterprise scaling is the priority: ODAIA aims to extend predictive intelligence across brands and therapeutic areas without rebuilding separate workflows for each deployment.
Get in touch with our MarTech Experts
Looking to publish a press release, guest article, interview or podcast? Connect with us.
GET FEATURED